Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC16772 structure
    GC16772Cortisone acetate
    CAS: 50-04-4
    纯度: >98.00%

    A synthetic glucocorticoid

  • GC16774 structure
    GC16774Boc-D-FMK
    CAS: 634911-80-1
    纯度: >95.00%

    Boc-D-FMK is a cell-permeable broad-spectrum caspase inhibitor that fully inhibits the pro-apoptotic effect of tumor necrosis factor-α (TNFα) with the half maximal inhibition concentration IC50 value of 39 μM .

  • GC16775 structure
    GC16775Rotenone
    CAS: 83-79-4
    纯度: >99.50%

    Rotenone是一种线粒体电子传递链复合物 I 抑制剂,可通过增强线粒体活性氧的产生来诱导细胞凋亡。

  • GC16794 structure
    GC16794UNC1215
    CAS: 1415800-43-9
    纯度: >98.00%

    Potent L3MBTL3 domain inhibitor

  • GC16795 structure
    GC16795DCA
    CAS: 2156-56-1
    纯度: >99.00% / >98.00%

    DCA 是癌细胞中的代谢调节剂';具有抗癌活性的线粒体。 DCA 抑制 PDHK,导致肿瘤微环境中的乳酸减少。 DCA 增加活性氧 (ROS) 生成并促进癌细胞凋亡。 DCA 也可作为 NKCC 抑制剂。

  • GC16818 structure
    GC16818BX-912
    CAS: 702674-56-4
    纯度: >99.50%

    A potent inhibitor of PDK1

  • GC16821 structure
    GC16821TAE226(NVP-TAE226)
    CAS: 761437-28-9
    纯度: >98.00%

    TAE226(NVP-TAE226)是一种强效的ATP竞争性抑制剂,能抑制多种酪氨酸蛋白激酶,尤其是FAK和IGF-IR激酶,其IC 50 值分别为5.5nM和140nM。

  • GC16823 structure
    GC16823Enniatin Complex
    CAS: 11113-62-5

    A complex mixture of ionophores

  • GC16827 structure
    GC16827ELR510444
    CAS: 1233948-35-0
    纯度: >98.00%

    An inhibitor of tubulin polymerization

  • GC16835 structure
    GC16835LY2228820
    CAS: 862507-23-1
    纯度: >99.50%

    A potent inhibitor of p38α MAP kinase

  • GC16843 structure
    GC16843Hydroxyurea
    CAS: 127-07-1
    纯度: >97.00% / >98.00%

    An antineoplastic agent

  • GC16853 structure
    GC168537,8-Dihydroxyflavone
    CAS: 38183-03-8
    纯度: >99.50% / >98.00%

    7,8-Dihydroxyflavone(7,8-二羟基黄酮)是一种高亲和力酪氨酸激酶受体B(TrkB)激动剂,IC 50 值为0.26μM 。

  • GC16868 structure
    GC16868Sulfasalazine
    CAS: 599-79-1
    纯度: >99.00% / >98.00%

    Sulfasalazine是一种磺胺类药物。

  • GC16869 structure
    GC16869Ixabepilone
    CAS: 219989-84-1
    纯度: >99.50%

    A broad-spectrum anticancer agent

  • GC16875 structure
    GC16875FLLL32
    CAS: 1226895-15-3
    纯度: >99.50%

    An inhibitor of JAK2/STAT3 signaling

  • GC16880 structure
    GC16880Flurbiprofen
    CAS: 5104-49-4
    纯度: >99.50%

    A non-selective COX inhibitor

  • GC16893 structure
    GC16893ICG 001
    CAS: 780757-88-2
    纯度: >99.50% / >98.00%

    ICG001 是一种靶向 Wnt/β-catenin 通路的小分子抑制剂。

  • GC16922 structure
    GC16922Kobe0065
    CAS: 436133-68-5
    纯度: >99.50%

    A selective Ras inhibitor

  • GC16948 structure
    GC16948Valinomycin
    CAS: 2001-95-8
    纯度: >98.00% / >95.00%

    缬霉素Valinomycin是一种十二肽抗生素,从几种链霉菌菌株中获得。

  • GC16976 structure
    GC16976Mitotane (Lsodren)
    CAS: 53-19-0
    纯度: >99.50%

    An inhibitor of steroidogenesis

  • GC16991 structure
    GC16991PQ 401
    CAS: 196868-63-0
    纯度: >99.50%

    An inhibitor of IGF-1R

  • GC17008 structure
    GC17008(+)-Apogossypol
    CAS: 66389-74-0

    (+)-Apogossypol 是一种泛 BCL-2 拮抗剂。 (+)-Apogossypol 与 Mcl-1、Bcl-2 和 Bcl-xL 结合,EC50 分别为 2.6、2.8 和 3.69 μM。

  • GC17023 structure
    GC17023HLCL-61
    CAS: 1158279-20-9
    纯度: >99.50%

    A PRMT5 inhibitor

  • GC17030 structure
    GC17030AZD6244(Selumetinib)
    CAS: 606143-52-6
    纯度: >99.00%

    AZD6244(Selumetinib)是一种口服小分子特异性MEK1/2蛋白ATP非竞争性抑制剂,IC 50 值为14.1± 0.79nM。